Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome Expands MGMT Methylation Agreement with Schering-Plough

NEW YORK (GenomeWeb News) - OncoMethylome Sciences said yesterday that it has extended an existing agreement with Schering-Plough to provide methylation testing in clinical trials focused on brain cancer and other cancers.
The agreement applies to OncoMethylome’s methylation assay for the MGMT biomarker, which has been shown to be methylated in a number of cancer types.
The company currently provides its MGMT methylation service for Schering-Plough for a multi-center clinical trial that is evaluating whether brain tumor patients can benefit from a more intensive temozolomide drug treatment regimen.
Under the terms of the new agreement, OncoMethylome’s assay will be used for MGMT methylation testing in “multiple national and international clinical trials” involving temozolomide in brain cancer and other cancers, the company said.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.